Apheresis in Neurological Disorders
Apheresis in Neurological Disorders
- Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
- 1 online resource (174 p.)
Open Access
Apheresis refers to an extracorporeal therapy which aims at removing pathological constituents from the patients' blood. Due to the development of new techniques as well as the discovery of novel autoimmune antibodies, it is increasingly recognized as an important therapeutic option for a variety of autoimmune-mediated neurological disorders, including multiple sclerosis, myasthenia gravis, autoimmune encephalitis, Guillain-Barré syndrome, and many others. Therapeutic plasma exchange (TPE) constitutes the standard method of apheresis for most indications, while immunoadsorption (IA) offers a more specific, low-risk alternative. Both methods aim at removing auto-antibodies from the blood. Evidence for most neurological diseases is still low. Interestingly, more recent developments suggest that apheresis is not limited to the removal of autoantibodies but may also be useful in neurodegenerative and possibly even in acute vascular disorders.
Creative Commons
English
9783039435852 9783039435869 books978-3-03943-586-9
10.3390/books978-3-03943-586-9 doi
Medicine and Nursing
acute relapsing multiple sclerosis Alzheimer's clinical syndrome antibody apheresis autoantibodies autoimmune encephalitis chronic inflammatory demyelinating polyneuropathy class IV CRP dementia Guillain-Barré syndrome immunoadsorption inflammation Inflammatory neuropathy limbic encephalitis multiple sclerosis Myalgic Encephalomyelitis/Chronic Fatigue Syndrome n/a neurological diseases NMDAR (N-Methyl-D-Aspartat) optic neuritis paraneoplastic paranodal antibodies plasma exchange plasmapheresis relapse ß2 adrenoreceptor autoantibody steroids stroke therapeutic apheresis therapeutic plasma exchange α1-Adrenergic receptor
Open Access
Apheresis refers to an extracorporeal therapy which aims at removing pathological constituents from the patients' blood. Due to the development of new techniques as well as the discovery of novel autoimmune antibodies, it is increasingly recognized as an important therapeutic option for a variety of autoimmune-mediated neurological disorders, including multiple sclerosis, myasthenia gravis, autoimmune encephalitis, Guillain-Barré syndrome, and many others. Therapeutic plasma exchange (TPE) constitutes the standard method of apheresis for most indications, while immunoadsorption (IA) offers a more specific, low-risk alternative. Both methods aim at removing auto-antibodies from the blood. Evidence for most neurological diseases is still low. Interestingly, more recent developments suggest that apheresis is not limited to the removal of autoantibodies but may also be useful in neurodegenerative and possibly even in acute vascular disorders.
Creative Commons
English
9783039435852 9783039435869 books978-3-03943-586-9
10.3390/books978-3-03943-586-9 doi
Medicine and Nursing
acute relapsing multiple sclerosis Alzheimer's clinical syndrome antibody apheresis autoantibodies autoimmune encephalitis chronic inflammatory demyelinating polyneuropathy class IV CRP dementia Guillain-Barré syndrome immunoadsorption inflammation Inflammatory neuropathy limbic encephalitis multiple sclerosis Myalgic Encephalomyelitis/Chronic Fatigue Syndrome n/a neurological diseases NMDAR (N-Methyl-D-Aspartat) optic neuritis paraneoplastic paranodal antibodies plasma exchange plasmapheresis relapse ß2 adrenoreceptor autoantibody steroids stroke therapeutic apheresis therapeutic plasma exchange α1-Adrenergic receptor